Logo image of ICLR

ICON PLC (ICLR) Stock Fundamental Analysis

NASDAQ:ICLR - Nasdaq - IE0005711209 - Common Stock - Currency: USD

127  +0.38 (+0.3%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to ICLR. ICLR was compared to 56 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of ICLR get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on ICLR. These ratings could make ICLR a good candidate for value investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year ICLR was profitable.
ICLR had a positive operating cash flow in the past year.
In the past 5 years ICLR has always been profitable.
Each year in the past 5 years ICLR had a positive operating cash flow.
ICLR Yearly Net Income VS EBIT VS OCF VS FCFICLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

With a decent Return On Assets value of 4.53%, ICLR is doing good in the industry, outperforming 76.79% of the companies in the same industry.
ICLR has a Return On Equity of 7.98%. This is amongst the best in the industry. ICLR outperforms 82.14% of its industry peers.
ICLR has a Return On Invested Capital of 6.71%. This is in the better half of the industry: ICLR outperforms 75.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ICLR is significantly below the industry average of 12.97%.
The 3 year average ROIC (5.80%) for ICLR is below the current ROIC(6.71%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.53%
ROE 7.98%
ROIC 6.71%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ICLR Yearly ROA, ROE, ROICICLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

Looking at the Profit Margin, with a value of 9.25%, ICLR is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
In the last couple of years the Profit Margin of ICLR has declined.
Looking at the Operating Margin, with a value of 14.54%, ICLR is in the better half of the industry, outperforming 76.79% of the companies in the same industry.
ICLR's Operating Margin has been stable in the last couple of years.
The Gross Margin of ICLR (29.06%) is worse than 75.00% of its industry peers.
ICLR's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 14.54%
PM (TTM) 9.25%
GM 29.06%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
ICLR Yearly Profit, Operating, Gross MarginsICLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ICLR is destroying value.
ICLR has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, ICLR has more shares outstanding
Compared to 1 year ago, ICLR has an improved debt to assets ratio.
ICLR Yearly Shares OutstandingICLR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ICLR Yearly Total Debt VS Total AssetsICLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

An Altman-Z score of 1.87 indicates that ICLR is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 1.87, ICLR perfoms like the industry average, outperforming 55.36% of the companies in the same industry.
ICLR has a debt to FCF ratio of 3.23. This is a good value and a sign of high solvency as ICLR would need 3.23 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 3.23, ICLR is doing good in the industry, outperforming 78.57% of the companies in the same industry.
A Debt/Equity ratio of 0.36 indicates that ICLR is not too dependend on debt financing.
ICLR has a Debt to Equity ratio (0.36) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 3.23
Altman-Z 1.87
ROIC/WACC0.79
WACC8.45%
ICLR Yearly LT Debt VS Equity VS FCFICLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

ICLR has a Current Ratio of 1.27. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
ICLR has a worse Current ratio (1.27) than 78.57% of its industry peers.
ICLR has a Quick Ratio of 1.27. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
ICLR's Quick ratio of 1.27 is on the low side compared to the rest of the industry. ICLR is outperformed by 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
ICLR Yearly Current Assets VS Current LiabilitesICLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

5

3. Growth

3.1 Past

ICLR shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.85%.
ICLR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.23% yearly.
The Revenue has decreased by -0.48% in the past year.
The Revenue has been growing by 24.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)2.85%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-8.07%
Revenue 1Y (TTM)-0.48%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.26%

3.2 Future

Based on estimates for the next years, ICLR will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.95% on average per year.
Based on estimates for the next years, ICLR will show a small growth in Revenue. The Revenue will grow by 4.86% on average per year.
EPS Next Y-3.26%
EPS Next 2Y2.4%
EPS Next 3Y4.89%
EPS Next 5Y9.95%
Revenue Next Year-3.83%
Revenue Next 2Y-0.79%
Revenue Next 3Y1.15%
Revenue Next 5Y4.86%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ICLR Yearly Revenue VS EstimatesICLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ICLR Yearly EPS VS EstimatesICLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10 20 30

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 9.26, the valuation of ICLR can be described as very reasonable.
Based on the Price/Earnings ratio, ICLR is valued cheaper than 100.00% of the companies in the same industry.
ICLR's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.03.
The Price/Forward Earnings ratio is 8.65, which indicates a very decent valuation of ICLR.
Based on the Price/Forward Earnings ratio, ICLR is valued cheaper than 96.43% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ICLR to the average of the S&P500 Index (21.94), we can say ICLR is valued rather cheaply.
Industry RankSector Rank
PE 9.26
Fwd PE 8.65
ICLR Price Earnings VS Forward Price EarningsICLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

ICLR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ICLR is cheaper than 100.00% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ICLR is valued cheaply inside the industry as 98.21% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.91
EV/EBITDA 8.21
ICLR Per share dataICLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100

4.3 Compensation for Growth

The decent profitability rating of ICLR may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.61
EPS Next 2Y2.4%
EPS Next 3Y4.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ICLR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ICON PLC

NASDAQ:ICLR (5/22/2025, 12:14:03 PM)

127

+0.38 (+0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)07-22 2025-07-22/amc
Inst Owners97.89%
Inst Owner Change0.88%
Ins Owners0.66%
Ins Owner ChangeN/A
Market Cap10.49B
Analysts79.23
Price Target194.25 (52.95%)
Short Float %1.49%
Short Ratio0.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.48%
Min EPS beat(2)-1.19%
Max EPS beat(2)0.23%
EPS beat(4)1
Avg EPS beat(4)-3.85%
Min EPS beat(4)-14.41%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.42%
EPS beat(12)4
Avg EPS beat(12)-1.63%
EPS beat(16)7
Avg EPS beat(16)-0.69%
Revenue beat(2)0
Avg Revenue beat(2)-2.08%
Min Revenue beat(2)-2.61%
Max Revenue beat(2)-1.54%
Revenue beat(4)0
Avg Revenue beat(4)-3.45%
Min Revenue beat(4)-6.75%
Max Revenue beat(4)-1.54%
Revenue beat(8)0
Avg Revenue beat(8)-2.81%
Revenue beat(12)0
Avg Revenue beat(12)-2.47%
Revenue beat(16)0
Avg Revenue beat(16)-2.13%
PT rev (1m)-21.57%
PT rev (3m)-26.44%
EPS NQ rev (1m)-3.82%
EPS NQ rev (3m)-8.76%
EPS NY rev (1m)-3.02%
EPS NY rev (3m)-7.06%
Revenue NQ rev (1m)-4.23%
Revenue NQ rev (3m)-5.53%
Revenue NY rev (1m)-4.2%
Revenue NY rev (3m)-5.45%
Valuation
Industry RankSector Rank
PE 9.26
Fwd PE 8.65
P/S 1.28
P/FCF 9.91
P/OCF 8.54
P/B 1.1
P/tB N/A
EV/EBITDA 8.21
EPS(TTM)13.72
EY10.8%
EPS(NY)14.68
Fwd EY11.56%
FCF(TTM)12.81
FCFY10.09%
OCF(TTM)14.87
OCFY11.71%
SpS99.23
BVpS115.08
TBVpS-37.13
PEG (NY)N/A
PEG (5Y)0.61
Profitability
Industry RankSector Rank
ROA 4.53%
ROE 7.98%
ROCE 8.49%
ROIC 6.71%
ROICexc 6.97%
ROICexgc 100.08%
OM 14.54%
PM (TTM) 9.25%
GM 29.06%
FCFM 12.91%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexcg growth 3Y-4.45%
ROICexcg growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score7
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 3.23
Debt/EBITDA 2.08
Cap/Depr 39.01%
Cap/Sales 2.07%
Interest Coverage 250
Cash Conversion 75.48%
Profit Quality 139.54%
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z 1.87
F-Score7
WACC8.45%
ROIC/WACC0.79
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)2.85%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-8.07%
EPS Next Y-3.26%
EPS Next 2Y2.4%
EPS Next 3Y4.89%
EPS Next 5Y9.95%
Revenue 1Y (TTM)-0.48%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.26%
Revenue Next Year-3.83%
Revenue Next 2Y-0.79%
Revenue Next 3Y1.15%
Revenue Next 5Y4.86%
EBIT growth 1Y8.27%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year6.74%
EBIT Next 3Y7.9%
EBIT Next 5Y7.35%
FCF growth 1Y191.78%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y139.85%
OCF growth 3Y15.78%
OCF growth 5Y25.55%